Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irum Khan

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
Haematologica|January 15, 2026
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemiaIvy E Abraham, Garth H Rauscher, Jerry Luo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2015
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell DiseaseSantosh L Saraf, Annie L Oh, Pritesh R Patel, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid LeukemiaPinkal M Desai, Janice Brown, Saar Gill, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Blood Advances|April 15, 2026
PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating CellsShiyu Xiao, Michihiro Kopbayashi, Yunpeng Bai, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
The Journal of Clinical Investigation|December 30, 2025
Mutant p53 promotes clonal hematopoiesis through generating a chronic inflammatory microenvironmentSisi Chen, Sergio Barajas, Sasidhar Vemula, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
NPJ Precision Oncology|February 26, 2026
FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AMLSanthosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, et al.
Haematologica|January 15, 2026
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemiaIvy E Abraham, Garth H Rauscher, Jerry Luo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2015
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell DiseaseSantosh L Saraf, Annie L Oh, Pritesh R Patel, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Blood|October 16, 2025
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical TrialsAndrew Hantel, Yating Wang, Angel Cronin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid LeukemiaPinkal M Desai, Janice Brown, Saar Gill, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Blood Advances|April 15, 2026
PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating CellsShiyu Xiao, Michihiro Kopbayashi, Yunpeng Bai, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
The Journal of Clinical Investigation|December 30, 2025
Mutant p53 promotes clonal hematopoiesis through generating a chronic inflammatory microenvironmentSisi Chen, Sergio Barajas, Sasidhar Vemula, et al.
Pageof 5